ATOSSA GENETICS INC

Inactive Instrument

Transcripts Atossa Genetics Inc Nasdaq

Equities

US04962H1005

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-15	Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	MT
05-15	Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	CI

Transcripts

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Atossa Therapeutics, Inc., Q2 2023 Earnings Call, Aug 14, 2023	14/08/23
Transcript : Atossa Therapeutics, Inc. - Special Call	04/05/23
Transcript : Atossa Therapeutics, Inc. - Special Call	25/08/22
Transcript : Atossa Therapeutics, Inc. - Special Call	30/11/21
Transcript : Atossa Therapeutics, Inc. Presents at LD Micro 500 Virtual Investor Conference, Sep-04-2020 09:00 AM	04/09/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer